Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended August 31, 2021. The firm ended the quarter with a $2.8 million net loss compared to fiscal Q1 2021’s net loss of $0.3 million. Among the company’s expenses for the quarter include $1.0 million in consulting fees and payroll, $0.2 …
KetamineOne Announces Two Studies Focused On PTSD, Depression
KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced the inaugural launch of not one, but two research studies. The studies will be centered around that of PTSD and depression. The first study, classified as a single arm, open label study of persons with PTSD, will examine persons undergoing …
Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract
Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1. The next round of pre-clinical trials focuses on the beneficial or adverse …
KetamineOne Sees Subsidiary Assist In Ketamine Clinical Trials
Ketamine continues to be a hot topic in terms of clinical trials, with KGK Science, a subsidiary of KetamineOne Capital (NEO: MEDI), this morning announcing its involvement in the latest trial. The contract research organization is set to assist in the process of the trials via facilities in Miami, Florida. The CRO has been contracted …
PharmaTher To Raise $10.0 Million Via Institutional Investor Financing
PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will be raising C$10.0 million via a financing conducted exclusively by H.C. Wainwright. The financing will see the company sell a total of 15.6 million units of the company price at $0.64 per each, with each …
Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022
Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing the company’s proprietary agonist BMB-101 to the investigational new drug stage enabling safety and toxicology studies for its potential treatment of Dravet syndrome. The biotech firm is selecting BMB-101 as the lead drug candidate in …
Numinus Wellness: Eight Capital Initiates With $1.10 Price Target
Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The fourth company initiated on this note is Numinus Wellness Inc. (TSXV: NUMI), with a C$1.10 12-month price target and buy rating while referring to the firm as “a diversified operator.” …
Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm
Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The last company to be initiated on is Bright Minds Biosciences (CSE: DRUG), with an C$11.50 price target, or a 67% upside and a buy rating. Eight Capital headlines the note, …
Cybin: Eight Capital Initiates With $9.53 Price Target
Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The second company on this list is Cybin Inc (NEO: CYBN), which they have given an C$8.15 12-month price target and buy rating. Cybin currently has 6 analysts covering the …
Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target
Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. They say that after a large influx of capital and “a growing body of clinical trial data on the use of psychedelics and related substances demonstrating a remarkable degree of …